Ranolazine
Ranolazine Brand names, Ranolazine Analogs
Ranolazine Brand Names Mixture
- No information avaliable
Ranolazine Chemical_Formula
C24H33N3O4
Ranolazine RX_link
No information avaliable
Ranolazine fda sheet
Ranolazine msds (material safety sheet)
Ranolazine Synthesis Reference
No information avaliable
Ranolazine Molecular Weight
427.537 g/mol
Ranolazine Melting Point
No information avaliable
Ranolazine H2O Solubility
Very slightly soluble
Ranolazine State
Solid
Ranolazine LogP
1.876
Ranolazine Dosage Forms
Tablets (extended release - 500 mg)
Ranolazine Indication
For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates.
Ranolazine Pharmacology
Ranolazine has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. It is the first new anti-anginal developed in over 20 years.
Ranolazine Absorption
Absorption is highly variable. After oral administration of ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of oral ranolazine relative to that from a solution is 76%.
Ranolazine side effects and Toxicity
In the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop.
Ranolazine Patient Information
AMITIZA™ may cause nausea. If this occurs, concomitant administration of food with AMITIZA™ may reduce symptoms of nausea. AMITIZA™ should not be administered to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe consult your physician.
Ranolazine Organisms Affected
Humans and other mammals
